Sol-Gel Technologies’ work to expand the treatment options for patients with the skin condition rosacea has paid off, with the FDA approving a product based on its microencapsulation technology.

Sol-Gel Technologies (NASDAQ:SLGL) said it is acquiring topically-applied drug patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings. Sol-Gel ...

NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...

LONDON--(BUSINESS WIRE)--The sol-gel coatings market is expected to grow by USD 2.63 billion during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 ...

Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel Technologies (NASDAQ:SLGL) shareholders have done very well over the last year, with ...

In the case of Sol-Gel Technologies Ltd. (NASDAQ:SLGL), the share price is up an incredible 940% in the last year alone. It's also good to see the share price up 106% over the last quarter. It is also ...

Sol-Gel Technologies reports increased Q1 revenue and expenses, with a net loss of $8.8 million compared to $6.3 million in 2024. Sol-Gel Technologies, Ltd., a clinical-stage dermatology company, ...

The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments. But the narrative may have changed. Sol-Gel delivered positive late-stage ...

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...

Researchers examined how poloxamer 407 micelles interact in saline, mimicking bodily fluids. Stronger inter-micellar ...